the Room · By Organisation
The room.
CGTI convenes the CDOs, CMOs, heads of manufacturing, clinical operations leads and regulatory strategy principals who are making the decisions that will define the field's next five years. Not a broad audience — a closed room.
The room · By Organisation
The principals.
The level the room is built at.
The level the room is built at.
the Room · By Organisation
The room.
CGTI convenes the CDOs, CMOs, heads of manufacturing, clinical operations leads and regulatory strategy principals who are making the decisions that will define the field's next five years. Not a broad audience — a closed room.
68
Confirmed leaders
2
Days · closed format
1
Room · one conversation
0
Open registrations
Who is in the room
The disciplines
the field requires.
Chief Development Officers
Development
at scale.
CDOs navigating IND-to-BLA timelines across autologous and allogeneic modalities. The development pathway is narrower than it appears. The decisions made at this stage set the ceiling for what manufacturing and access can achieve.
Chief Medical Officers
Clinical
accountability.
CMOs and clinical operations principals managing Phase II and III programmes in cell and gene therapy. Regulatory endpoints, safety signals and protocol design are the operating context — not aspiration.
Heads of Manufacturing
Process
decisions.
Manufacturing leads at sponsors and CDMOs defining vector supply strategy, bioreactor platform selection and batch release architecture. The manufacturing constraint is where most cell and gene programmes stall.
Regulatory & Market Access
The pathway
to the patient.
Regulatory affairs VPs and market access strategists who have navigated EMA and FDA approvals for advanced therapies. The dossier is not the constraint — the reimbursement architecture is.
Supply Chain Principals
Cold chain
at the edge.
Supply chain leads managing vein-to-vein logistics for autologous products. Chain of identity, cold chain integrity and site activation timelines are the operational frontier of advanced therapy delivery.
Strategic Technology Partners
Infrastructure
in the room.
A small number of technology and platform partners whose capabilities are directly relevant to the decisions being made. In the room, not on a stand. A position. Not a placement.
Who is in the room
The disciplines
the field requires.
Chief Development Officers
Development
at scale.
CDOs navigating IND-to-BLA timelines across autologous and allogeneic modalities. The development pathway is narrower than it appears. The decisions made at this stage set the ceiling for what manufacturing and access can achieve.
Chief Medical Officers
Clinical
accountability.
CMOs and clinical operations principals managing Phase II and III programmes in cell and gene therapy. Regulatory endpoints, safety signals and protocol design are the operating context — not aspiration.
Heads of Manufacturing
Process
decisions.
Manufacturing leads at sponsors and CDMOs defining vector supply strategy, bioreactor platform selection and batch release architecture. The manufacturing constraint is where most cell and gene programmes stall.
Regulatory & Market Access
The pathway
to the patient.
Regulatory affairs VPs and market access strategists who have navigated EMA and FDA approvals for advanced therapies. The dossier is not the constraint — the reimbursement architecture is.
Supply Chain Principals
Cold chain
at the edge.
Supply chain leads managing vein-to-vein logistics for autologous products. Chain of identity, cold chain integrity and site activation timelines are the operational frontier of advanced therapy delivery.
Strategic Technology Partners
Infrastructure
in the room.
A small number of technology and platform partners whose capabilities are directly relevant to the decisions being made. In the room, not on a stand. A position. Not a placement.
Organisations in the room
The room.
Confirmed organisations from pharma, biotech, CDMO, equipment and strategic advisory sectors. The wall reflects the room as confirmed — no placeholders, no aspirational entries.
The room · By Organisation
The room.
The principals shaping cell and gene therapy at scale. Across development, manufacturing, regulatory and clinical delivery.
By invitation. By relevance. By room.
The level the room is built at.